News Detail - Relief Therapeutics Holdings SA

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Relief Therapeutics Holding SA / Key word(s): Conference
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
07.09.2022 / 07:00 CET/CEST

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Geneva, Switzerland, September 7, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today announced that Jack Weinstein, Chief Financial Officer and Treasurer, will present a company overview during the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 12-14, 2022.

Date: Tuesday, September 13, 2022
Time: 1:30 pm ET

Management will host one-on-one meetings during the event. Institutional investors who are registered for the conference can log into to request a meeting with the company.

A live webcast of Relief’s presentation will be available on the Company’s website at: and will be archived for a period of 90 days after the conference.


Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases and connective tissue disorders. Relief’s diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria ("PKU"). Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders (“UCDs”) and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the FDA. In addition, Relief is commercializing several legacy products via licensing and distribution partners.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit Follow Relief on LinkedIn.

Jack Weinstein
Chief Financial Officer and Treasurer
Rx Communications Group
Michael Miller



Additional features:

File: Press release

End of Media Release

show this
30 August 2023